文献速递银屑病与炎症性皮肤病

Deucravacitinib治疗中重度斑块状银屑病长达3年的安全性与疗效:随机临床试验的开放标签扩展研究

Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years: An Open-Label Extension of Randomized Clinical Trials.
PubMed 文献 · JAMA Dermatol · 2025-01-01

该研究整合了POETYK PSO-1、PSO-2两项3期随机双盲试验及其非随机长期扩展(LTE)试验,评估deucravacitinib 6 mg每日一次治疗中重度斑块状银屑病长达3年(第148周)的安全性和疗效。结果显示,随着治疗时间延长,不良事件、严重不良事件、因不良事件停药和死亡的发生率保持稳定或下降,临床应答率维持至3年。

要点

  • deucravacitinib 6 mg每日一次治疗中重度斑块状银屑病,长达3年的安全性特征与短期一致。
  • 3年累积期间不良事件发生率较1年降低或相似,未出现新的安全性信号。
  • 临床应答率(PASI 75/90、sPGA 0/1)在3年治疗期间得以维持。

核心结论

  • 对POETYK PSO-1、PSO-2及LTE试验的整合分析表明,deucravacitinib连续治疗3年具有一致的安全性特征和持久的临床应答。

研究设计与样本

  • PSO-1/PSO-2为全球、52周、随机双盲3期试验,患者按1:2:1随机接受口服安慰剂、deucravacitinib 6 mg每日一次或阿普斯特30 mg每日两次。
  • 完成52周治疗后患者可入组预设的非随机长期扩展试验,接受开放标签deucravacitinib 6 mg每日一次治疗。
  • 安全性分析纳入1519例接受至少1剂deucravacitinib的患者;疗效分析纳入从母试验第1天起连续接受deucravacitinib并进入LTE的513例患者。

主要发现

  • 1年与3年累积期间每100人年的暴露调整发生率分别为:不良事件229.2 vs 144.8(95%CI 215.4-243.9 vs 137.1-153.0),严重不良事件5.7 vs 5.5(95%CI 4.4-7.4 vs 4.7-6.4),因不良事件停药4.4 vs 2.4(95%CI 3.3-5.9 vs 2.0-3.0),死亡0.2 vs 0.3(95%CI 0.1-0.8 vs 0.2-0.6)。
  • 1年与3年累积期间最常见不良事件(EAIR每100人年≥5)分别为:鼻咽炎26.1 vs 11.4(95%CI 23.0-29.8 vs 10.2-12.7),COVID-19 0.5 vs 8.0(95%CI 0.2-1.2 vs 7.1-9.1),上呼吸道感染13.4 vs 6.2(95%CI 11.3-16.0 vs 5.4-7.2)。
  • 关注的不良事件(包括带状疱疹、主要不良心血管事件和恶性肿瘤)的EAIR保持较低水平,且1年与3年累积期间降低或相当。
  • 临床应答率维持至3年。

关键数值与推荐

  • 疗效评估指标包括银屑病面积和严重程度指数较基线改善≥75%或≥90%(PASI 75/90)以及静态医生总体评估评分为0(清除)或1(几乎清除)(sPGA 0/1)。
  • 安全性结局在至少接受1剂deucravacitinib的患者中评估;疗效结局在从母试验第1天起接受deucravacitinib并继续进入LTE试验的患者中评估。

临床怎么用

  • 对于中重度斑块状银屑病患者,deucravacitinib 6 mg每日一次可作为长期治疗选择,其安全性和疗效在3年内保持稳定。
  • 长期治疗期间需关注带状疱疹、主要不良心血管事件和恶性肿瘤等关注的不良事件,但发生率保持较低。

局限性

  • LTE试验为非随机、开放标签设计。
  • 全球COVID-19大流行高峰与LTE试验期重合。
  • 疗效分析仅纳入从母试验第1天起连续接受deucravacitinib并进入LTE的患者,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Safe and effective long-term treatments for moderate to severe plaque psoriasis are needed. OBJECTIVE: To evaluate the long-term safety and efficacy of deucravacitinib through 3 years (week 148) in the randomized POETYK PSO-1, PSO-2, and nonrandomized long-term extension (LTE) trials. DESIGN, SETTING, AND PARTICIPANTS: PSO-1/PSO-2 were global, 52-week, randomized, double-blinded phase 3 trials in patients with moderate to severe plaque psoriasis. After completing 52 weeks of treatment in PSO-1/PSO-2, patients could enroll in the prespecified, ongoing, nonrandomized LTE trial. The peak of the global COVID-19 pandemic coincided with the LTE trial. Patient enrollment in the LTE started August 12, 2019; safety and efficacy were assessed through June 15, 2022; and these data were analyzed through June 28, 2024. INTERVENTIONS: The PSO-1/PSO-2 trials randomized patients 1:2:1 to oral placebo, deucravacitinib, 6 mg once daily, or apremilast, 30 mg twice daily. Patients enrolling in the LTE trial received open-label deucravacitinib, 6 mg once daily. MAIN OUTCOMES AND MEASURES: Safety outcomes were evaluated in patients who received 1 or more doses of deucravacitinib. Efficacy outcomes included 75% or greater or 90% or greater reduction from baseline in Psoriasis Area and Severity Index (PASI 75/90) and static Physician Global Assessment scores of 0 (clear) or 1 (almost clear) (sPGA 0/1) and were assessed in patients who received deucravacitinib treatment from day 1 of the parent trials who continued in the LTE trial. RESULTS: Of 1519 patients who received 1 or more doses of deucravacitinib, 513 received continuous deucravacitinib treatment from day 1 and entered the LTE trial. Exposure-adjusted incidence rates (EAIRs) per 100 person-years were decreased or similar in the 1-year vs 3-year cumulative periods, respectively, for adverse events (AEs) (229.2 vs 144.8; 95% CI, 215.4-243.9 vs 137.1-153.0), serious AEs (5.7 vs 5.5; 95% CI, 4.4-7.4 vs 4.7-6.4), discontinuations due to AEs (4.4 vs 2.4; 95% CI, 3.3-5.9 vs 2.0-3.0), and deaths (0.2 vs 0.3; 95% CI, 0.1-0.8 vs 0.2-0.6). Incidence rates of the most common AEs (EAIR per 100 person-years ≥5) during the 1-year and 3-year cumulative periods, respectively, were nasopharyngitis (26.1 vs 11.4; 95% CI, 23.0-29.8 vs 10.2-12.7), COVID-19 (0.5 vs 8.0; 95% CI, 0.2-1.2 vs 7.1-9.1), and upper respiratory tract infection (13.4 vs 6.2; 95% CI, 11.3-16.0 vs 5.4-7.2). EAIRs for AEs of interest, including herpes zoster, major adverse cardiovascular events, and malignant diseases, remained low and were decreased or comparable between the 1-year and 3-year cumulative periods. Clinical response rates were maintained through 3 years. CONCLUSIONS AND RELEVANCE: The findings of this integrated analysis of the phase 3 POETYK PSO-1, PSO-2, and nonrandomized LTE trials demonstrate a consistent safety profile and durable clinical response of continuous treatment with deucravacitinib through 3 years of treatment in patients with psoriasis. TRIAL REGISTRATION: ClinicalTrials.gov Identifiers: NCT03624127, NCT03611751, and NCT04036435.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Armstrong AW, Lebwohl M, Warren RB, et al. Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years: An Open-Label Extension of Randomized Clinical Trials. JAMA Dermatol. 2025. PMID: 39602111. doi:10.1001/jamadermatol.2024.4688

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。